Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia
Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target ...
The Bakersfield Californian14h
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for ...
FDA sets PDUFA Action Date of June 28, 2025 ...
MM&M2d
Post-election prescription: Why Trump’s return could disrupt pharma
From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...
Physicians Committee4d
Innovative FDA Program to Evaluate Nonanimal Organ-on-a-Chip Technology
In an exciting development for drug development and patient care, the FDA has officially accepted the first submission of an organ-on-a-chip technology under its Innovative Science and Technology ...
No, Trump’s drug program for terminal patients didn't save ‘thousands’ of lives
Medical experts who’ve studied the experimental treatment program, however, say there’s no evidence to support Trump’s claims ...
FiercePharma6d
Election spotlight: As Harris and Trump face off, what's at stake for pharma?
Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following ...